Updated March 2026
Dupixent Cancer Litigation Is Emerging Nationwide
Lawsuits allege Dupixent (dupilumab) may increase cancer risk in some patients by suppressing IL-4/IL-13 immune pathways involved in tumor surveillance.
Key Facts
- Dupixent is a monoclonal antibody that inhibits IL-4 and IL-13 signaling.
- FDA approval began in 2017 and expanded across multiple inflammatory conditions.
- It has been prescribed to more than 900,000 patients.
- Annual global sales have exceeded $13 billion.
- Post-marketing reports include lymphoma, skin cancer, and other solid tumors.
- Current litigation is in the pre-MDL stage.
Defendants Commonly Named
Sanofi and Regeneron Pharmaceuticals.
Who May Qualify
- People who used Dupixent for eczema, asthma, nasal polyps, COPD, chronic hives, or related indications.
- People diagnosed with cancer during treatment or after discontinuation.
- Families pursuing wrongful-death claims tied to Dupixent-associated malignancies.